Molecular features of dormancy in ER plus breast cancers

被引：0
|
作者：
Clarke, Robert
Dixon, Michael J.
Jin, Lu
Turnbull, Aaron
Hu, Rong
Zwart, Alan
Wang, Yue
Xuan, Jianhua
Sengupta, Surojeet
Renshaw, Lorna
Sims, Andrew
Liu, Minetta C.
机构：
[1] Georgetown Univ, Med Ctr, Washington, DC 20007 USA
[2] Univ Edinburgh, Edinburgh, Midlothian, Scotland
[3] Virginia Tech, Arlington, VA USA
[4] Mayo Clin, Rochester, MN USA
来源：
CANCER RESEARCH | 2018年 / 78卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P4-04-10
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Investigating the relationship of socioeconomic status on the molecular biology of ER plus breast cancer
    DeWitt, Jerry T.
    CANCER RESEARCH, 2024, 84 (03)
  • [42] Developmental and therapeutic implications of molecular profiles of ER-positive and ER-negative breast cancers.
    Perou, CM
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S3 - S3
  • [43] Initial experience of dedicated breast PET imaging of ER plus breast cancers using [F-18]fluoroestradiol
    Jones, E. F.
    Ray, K. M.
    Mukhtar, R.
    Li, W.
    Franc, B. L.
    Esserman, L. J.
    Joe, B. N.
    Pampaloni, M. H.
    Hylton, N. M.
    CANCER RESEARCH, 2019, 79 (04)
  • [44] Patient poverty burden influences the molecular biology of ER plus breast cancer
    DeWitt, Jerry T.
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2024, 33 (09)
  • [45] Response to neoadjuvant trastuzumab and chemotherapy in ER plus and ER-HER2-positive breast cancers: Gene expression analysis
    Bianchini, G.
    Prat, A.
    Pickl, M.
    Belousov, A.
    Koehler, A.
    Semiglazov, V.
    Eiermann, W.
    Tjulandin, S.
    Biakhov, M.
    Lluch, A.
    Zambetti, M.
    Vazquez Mazon, F. J.
    Baselga, J.
    Gianni, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [46] In vivo model of dormancy in ER breast cancer to bone metastasis
    Gawrzak, S.
    Guiu, M.
    Urosevic, J.
    Fernandez, E.
    Pavlovic, M.
    Gomis, R. R.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : S82 - S82
  • [47] Multiomics analysis of matched ER plus primary and recurrent breast cancers on or after adjuvant endocrine therapy
    Martinez-Perez, Carlos
    Kay, Charlene
    Meehan, James
    Dixon, J. Michael
    Turnbull, Arran K.
    CANCER RESEARCH, 2023, 83 (05)
  • [48] Functional Pathology of ER Positive Breast Cancers
    Zwart, W.
    JOURNAL OF PATHOLOGY, 2018, 246 : S3 - S3
  • [49] ALT NHEJ is a therapeutic target in hormone therapy resistant ER/PR/HER plus and ER/PR/HER-breast cancers
    Tobin, Lisa A.
    Chumsri, Saranya
    Staats, Paul
    Brodie, Angela
    Tomkinson, Alan
    Rassoo, Feyruz
    CANCER RESEARCH, 2011, 71
  • [50] Imaging features of breast cancers on digital breast tomosynthesis according to molecular subtype: association with breast cancer detection
    Lee, Su Hyun
    Chang, Jung Min
    Shin, Sung Ui
    Chu, A. Jung
    Yi, Ann
    Cho, Nariya
    Moon, Woo Kyung
    BRITISH JOURNAL OF RADIOLOGY, 2017, 90 (1080):
12345